Skip to content

Clinical study on the safety, efficacy, and accelerated rehabilitation of perioperative application of esketamine in patients undergoing urological surgery

Clinical study on the safety, efficacy, and accelerated rehabilitation of perioperative application of esketamine in patients undergoing urological surgery

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071295
Enrollment
Unknown
Registered
2023-05-10
Start date
2023-05-10
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cysts, adrenal masses, renal tumors

Interventions

Group K1:Traditional laparoscopic urological surgery under esketamine anesthesia
Group K2:Micro Hand S surgical robot-assisted urological surgery under esketamine anesthesia
Group C:Traditional laparoscopic urological surgery under conventional anesthesia

Sponsors

Xuzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. ASA grade I ~ III; 3. BMI:18-32kg/m^2; 4. Patients who plan to undergo robot-assisted or traditional endoscopic renal cyst decompression, adrenal mass resection, and total or partial nephrectomy; 5. Voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe hypertension, pulmonary hypertension, cranial pressure or intraocular pressure; 2. Patients with heart, liver, lung, kidney and other vital organ diseases who cannot tolerate the operation; 3. Previous gastric perforation, intestinal perforation, intestinal adhesion laxity, and previous operations on the target site of this operation; 4. Have a history of epilepsy or mental illness; 5. Allergic to esketamine or other narcotic drugs; 6. Patients with severe systemic infection; 7. Other conditions that the investigator considers inappropriate to participate in this clinical study.

Design outcomes

Secondary

MeasureTime frame
Visual analogue scale;Incidence of postoperative nausea and vomiting;Consumption of intraoperative sedative and analgesic drugs;Dosage of relief analgesics;QoR-15 (15 recovery quality rating scale);Perioperative adverse reactions;

Primary

MeasureTime frame
Blood pressure;Heart rate;

Countries

China

Contacts

Public ContactWang Liwei

Xuzhou Central Hospital

doctorlww@sina.com+86 189 5217 0255

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026